Cause of the message: Update
Company: Chemesis International (WKN A2NB26)
Target price medium term 4.00 EUR
Entry into the lucrative CBD market promises besides cannabis production further millions of sales - chart technical outbreak is imminent!
With today's news, our Cannabis Top Pick Chemesis International (WKN A2NB26 ) announces its entry into the lucrative CBD market. The US CBD market could reach $ 845 million by 2019 and more than $ 2 billion by 2022. With the adoption of the Farm Bill of 2018, the Federal CBD market will allow US territories such as Puerto Rico to transport their hemp products across the states (such as Puerto Rico) to the US markets. This allows the company additional sales branches and thus further millions of sales. The targeted $ 16.5 million sales by the end of the current fiscal year (as at 30.06.2019), therefore, in our opinion, a very conservative estimate because we expect much higher sales.
With existing infrastructure, Natural Ventures will be able to effectively add CBD products alongside currently available products. The company expects products to be launched in pharmacies throughout Puerto Rico by the second quarter of 2019. The first products include tinctures, balms, vape pens and sprays.
We expect more significant news in the coming weeks, currently working on many fronts - an outbreak of the 2 Euro mark is in our opinion, only a matter of time. Remember, due to the high insider participation, only 16 million shares are in the free float. A rapid, huge price increase is therefore absolutely within the range of the possible.
All in all, Chemesis International (WKN A2NB26 ) fulfills the requirements to become the high flyer in the cannabis sector in 2019, thanks to its excellent strategic orientation and very clever acquisitions. The success of the company should also draw attention to industry leaders such as Canopy Growth (WKN A140QA) or Aphria (WKN A12HM0) .
As a result, Chemesis expects total revenues of $ 16.5 million for the fiscal year ended June 30, 2019 and a gain of approximately $ 2 million. what an exceptionally good result for such a young company.
Since Chemesis International (WKN A2NB26 ) is already expecting revenues and earnings to triple by the financial year 2020, a revaluation of the share is more than justified above the current price level. A course to the 4 euros is quite possible.
Natural Ventures has begun cultivating high potency CBD strains and expects full production capacity by the second quarter of 2019. The company was able to cross genetics that allowed for increased CBD levels, and the seed strains were fully licensed to the Puerto Rico Health Authority registered. In addition, the subsidiary holds all necessary licenses for the cultivation and production of hemp-derived products.
"The patients in Puerto Rico know and trust the Natural Ventures brand," said Edgar Montero, Chief Executive Officer. "The company believes that this relationship with patients will give us a head start and an effective entry into the CBD market, enabling us to quickly get our products to the shelves of pharmacies around the island "
Cannabis Highflyer 2019! Chemesis facing rapid development - benefit now in time!
In recent months, we have already reported in detail on our Cannabis Top Pick Chemesis International (WKN A2NB26 ). Due to the positive developments of the company in recent weeks, we are convinced that Chemesis will become the highflyer in the cannabis industry in 2019!
Especially now that the development of the whole cannabis market has turned and overall there is a very positive mood, Chemesis International (WKN A2NB26 ) will be able to benefit enormously.
We would like to summarize the reasons for our assessment here:
- Chemesis is represented in three extreme fast growing cannabis markets of California, Puerto Rico and Colombia
- The Latin American market offers huge development potential and is expected to have a market volume of $ 4.2 billion by 2028. Chemesis has positioned itself in good time today to benefit from this development.
- Mega-acquisition with more than 4 million square meters of acreage in Colombia made Chemesis the largest cannabis producer in Latin America in terms of area
- Through a broad product portfolio, Chemesis can offer the right products for the respective market, such as cannabis oils, medicinal cannabis or nutritional supplements
- By taking over already bursting local cannabis producers, the production of cannabis products was started immediately, thereby generating sales.
- Therefore, Chemesis expects total revenues of $ 16.5 million for the fiscal year ended June 30, 2019 and a gain of approximately $ 2 million. what an exceptionally good result for such a young company.
- For marketing purposes, among others, the well-known in the US as "Silent Bob" very famous actor and director Kevin Smith. Through its social media presence alone with over 12.4 million followers, Chemesis increases its awareness for cannabis users. The newly launched cannabis brand "Jay an Silent Bob" has already reached an order volume of over $ 100,000 in the first week of sales.
In a very interesting podcast with Chemesis International (WKN A2NB26 ) CEO Edgar Montero, they can learn even more about the future development of the company.
PODCAST with Chemesis CEO Edgar Montero
All in all, Chemesis International (WKN A2NB26 ) fulfills the requirements to become the high flyer in the cannabis sector in 2019, thanks to its excellent strategic orientation and very clever acquisitions. The success of the company should also draw attention to industry leaders such as Canopy Growth (WKN A140QA) or Aphria (WKN A12HM0) .
Since Chemesis International (WKN A2NB26 ) is already expecting revenues and earnings to triple by the financial year 2020, a revaluation of the share is more than justified above the current price level. A course to the 4 euros is quite possible.
Do not miss the last chance to enter here in time!
Here you can subscribe to our free newsletter - LINK
After entering the cannabis beverage sector, entry into the cannabis food sector follows - first mover before revaluation!
Chemesis International (WKN A2NB26 ) recently announced another significant milestone with its entry into the beverage sector . As the company has just announced, its subsidiary Natural Ventures has entered into a licensing agreement to produce the Dragonflass Flake and Bake ("Dragonglass") cannabis powder for Project 1493 LLC, a subsidiary of GSRX Industries, Inc. Dragonglass will be available exclusively to Green Spirit RX dispensaries throughout Puerto Rico. Thus, entry into the cannabis food sector is perfect, which will flush additional revenue into the fund.
Dragonglass is made using patent pending technology that allows consumers to consume cannabis in a variety of different ways, flavors and colors. The dried activated THC powder or THC flakes are completely natural and contain zero calories, sugars, fats or alcohols and are 100% vegan. The powder or flakes are made via a proprietary, water-based cannabinoid infusion method that allows users to consume them after a waiting period of 7-15 minutes. Dragonglass is available in a variety of flavors, including mint, cinnamon, lemon lime and even cayenne for cooking. Dragonglass can be administered sublingually, ingested, microdosed and added to food or drink.
Today's news in detail:
GSRX Industries Inc. (OTCQB: GSRX), one of the largest operators of medical cannabis distribution centers in Puerto Rico (under the brand name Green Spirit RX), has five medical cannabis distribution centers on the island in San Juan-Puerto Nuevo, San Juan-Hato Ray, Carolina , Dorado and Fajardo. These pharmacies are located in prime, high-traffic areas, in close proximity to tourist centers and hotels. In anticipation of growing demand for cannabis products, including foods such as Dragonglass, Green Spirit RX has acquired five more locations in Puerto Rico, which are expected to open in 2019. The company already has pre-qualified licenses for transport and home patient supplies in Puerto Rico. In addition, Project 1493 and Green Spirit RX will direct all marketing efforts in Puerto Rico to ensure that cannabis users are informed about Dragonglass and its benefits
"We are very pleased with the agreement to offer Dragonglass to cannabis users in Puerto Rico," said Edgar Montero, CEO of Chemesis. "Chemesis expects patent-pending proprietary technology to revolutionize Puerto Rican industry with its rapid deployment and versatile consumption methods, and Natural Ventures will continue to expand its capacity to meet the growing demand of the Puerto Rican cannabis industry."
First mover in the cannabis beverage sector - further millions of sales expected - Buy-Sentiment Share!
A few days ago, our Cannabis Top Pick Chemesis International (WKN A2NB26 ) was one of the first companies to even announce the launch of an Energy Shot, a Sleep Shot and a Calming Shot, making Chemesis one of the first companies to do so Puerto Rico will produce and distribute beverage products.
The initial launch of these all-natural ingredients will include an Energy Shot, a Sleep Shot, and a Calm Shot. Following initial delivery to selected pharmacies this week, the company expects these products to be available throughout its pharmacy network in Puerto Rico within the next 30 days.
Mega acquisition with over 4 million square meters of acreage in Colombia makes Chemesis the largest cannabis producer in terms of area
Chemesis International (WKN A2NB26 ) recently announced the completion of its mega-acquisition in Colombia. The company had more than 43 million sqf. fully licensed acreage (equivalent to 1,000 acres) is binding and becoming one of the largest cannabis producers in the industry. By way of comparison, Cannabis Gigant Canopy Growth (WKN A140QA)currently has 5 million sqf. in Canada and is thus unchallenged in 1st place.
A significant increase in price in the direction of the 2 EUR mark is therefore expected in the coming weeks. Considering that the emerging Latin American cannabis market is estimated to have a market value of $ 4.2 billion by 2028 and the potential of the Colombian cannabis market alone is estimated at over $ 664 million, we believe that mid-term prices of $ 4- $ 5 are absolutely in the range the possible.
As you already know, there are currently only 16 million free float shares and the insiders hold a majority of the shares. Therefore, we are of the opinion that an increase in price will be made very quickly and explosively for that very reason, so do not miss out on positioning yourself in time.
We expect further positive newsflow in the coming weeks, and a takeover can no longer be ruled out, because the company is in an excellent position!
The Acquisition in Detail:
Chemesis International (WKN A2NB26 ) will finalize the acquisition of the Colombia-based La Finca Interacviva-Arachna Med ("La Finca") for $ 8,000,000 in shares at an agreed price of $ 1.25 per share Share and has agreed to pay another $ 5,500,000 in the next 24 months. All issued shares will be subject to a 36-month hold period.
La Finca is an integrated cannabis company fully licensed since October 2017 and operating in Colombia. La Finca has over 1,000 acres (equivalent to 43 million sq. Ft.) Of open land and aggressively explores expansion opportunities. You are a founding member of the Association for the Promotion of Hemp Growing, a nonprofit organization focused on training and promoting the expansion of cannabis plantations while ensuring the cultivation of quality crops through technical advice. The company's cultivation program is based on a decentralized model with partner farms across the country, allowing smallholders to grow high-quality crops quickly. Currently, La Finca is in partnership with over 2,000 farmer families in Colombia through various cooperatives, which can be added to their land package.
La Finca is also partnering with the largest university in Colombia, Universidad Nacional, to develop seed to improve yields of biomass and flowers while shortening planting cycles. La Finca also has a partnership with Universidad Distral, which focuses on the educational aspects of cannabis cultivation. The university provides remote education and classroom instruction to educate farmers on the cultivation of cannabis plants, thus ensuring their ability to produce high-quality crops.
La Finca currently has over $ 2.3 million in working capital to expand its operations and has several production relationships. The company has a manufacturing agreement for INVIMA (FDA Equivalent) licensed beauty products under the La Finca brand. The company is heavily involved with INVIMA to ensure compliance with all rules and health regulations.
Due to the proximity to the equator, Colombia has a year-round 12-hour solar cycle, resulting in a harvest of 365 days a year 1 allowed. The mountain regions of Colombia offer different thermal levels, which allow simultaneous cultivation in different climates. Colombia also has many free trade agreements that will allow low-cost worldwide export of cannabis product. As a result, the company believes that La Finca is well-positioned in a country, that its regulations are rapidly adjusted, providing a lucrative investment opportunity for both short-term and long-term growth.
"With the completion of this acquisition, Chemesis will significantly expand its presence in Latin America," said Chemesis CEO Edgar Montero. "La Finca is developing as planned and has submitted all necessary documents to expand its acreage to 1,060 acres at the Department of Justice."
The past top NEWS and our detailed first recommendation - find out more!
Exclusive agreement for the production, sale and distribution of Quick Strips with cannabis oil! Share still cheap compared to the peer group!
Another sales guarantee was announced recently and represents another unique selling point to set itself apart from the competition. The company and Rapid Dose Therapeutics Inc. ("RDT"), a Canadian biotechnology company offering disruptive proprietary drug delivery technologies to improve patient outcomes, has signed a definitive agreement that will allow Chemesis to co-author QuickStrips (TM) To produce cannabis oil.
RDT's innovative QuickStrip is an easy-to-use, safe and effective oral and rapid-release drug delivery system that delivers precise delivery and strength, and was co-developed with McMaster University by the prestigious Adronov Research Group.
Under the terms of the MOU, Chemesis has the rights to produce, distribute and sell the exclusive rights to the QuickStrip products for the Californian market and beyond. With Chemesis' state-of-the-art facility, the company believes that this partnership with RDT will further strengthen its position in the California cannabis market by allowing the company to use a convenient drug delivery system that can and will target a variety of consumers cannabis products in a new way. The company will continue to position itself to capitalize on this growing market with innovative and effective products.
"RDT is an innovator in the world of drug delivery, making it an excellent opportunity for Chemesis," said Chemesis CEO Edgar Montero .
"QuickStrips includes therapeutic products and they also provide a drug delivery system that is fast, convenient, precise, discreet, convenient to travel and an alternative for those who have problems swallowing pills." The company believes that this drug delivery system can appeal to a wide range of consumers and we look forward to distributing the products in the near future. "
"RDT is pleased to partner with Chemesis to provide consumers in California with a method of administration they can depend on, marking the beginning of the move away from inhalation to the dosage of therapeutic products," said Mark Upsdell, CEO of RDT , "Chemesis has developed strategies, partnerships, high-quality oil production and distribution channels that enable QuickStrip to rapidly expand into the Californian market and we will work directly with Chemesis to develop additional white label partnerships with manufacturers and distributors in California."
Cooperation with the son of Bob Marley - Sales for the brand JuJu Royal promises further millions of sales!
The company has entered into a settlement and distribution agreement for ultra premium brand Julian Marley JuJu Royal (TM). Packaging, processing and distribution will be carried out for all JuJu Royals businesses in Southern California. This is another milestone for the company and should generate millions of dollars in revenue.
Furthermore, we expect a significant acquisition of a South American cannabis producer in the coming days. With the news (LINK) from 11.09.2018, the company already announced that as part of a long-term growth strategy, several international acquisitions will be audited. This would be a further milestone for the company and should lift prices well above the 2 euro mark.
The highly coveted brand includes carefully crafted high-quality cannabis products that are handled at Desert Zen's manufacturing facility in Cathedral City, California. These products meet the high demands of Julian Marley and are currently sold in several countries. The product catalog includes a variety of cannabis products and varieties that are unique to JuJu Royal.
"The agreement for JuJu Royal is another example of Chemesis' ability to consistently deliver quality products, confirming the management's business plan and growth strategy," said CEO, Edgar Montero. "Brands in need of quality services are recognizing our ability to consistently manage all of their high-value products with full compliance and as Chemesis' awareness of the market continues to grow, we expect a further increase in the need for reliable quality services such as this one ensure that we are able to build a stable long-term value for the business. "
Admission to Canadian Cannabis ETF Fund Company Sees Great Potential in Chemesis! Share continues in uptrend!
The company has recently been included in an exclusive Cannabis ETF dedicated to smaller and mid-sized cannabis producers with great market potential. (NEWS)
The Horizon ETF Management Group currently manages assets of more than $ 11 billion in 81 ETFs on major Canadian exchanges.
Steve Hawkins, president and chief executive officer of Horizons ETFs said about the fund in which Chemesis was added as a new company:
"The fund offers investors the opportunity to gain exposure to the marijuana sector, and we specifically target emerging companies in the sector to participate in the overall growth cycle of these companies."
For Chemesis this is further confirmation that the good work of the company is also being noticed by big investors. In the coming weeks, further positive newsflow is expected. We therefore expect the next price break in the direction of 2 euros.
With our free newsletter we inform you about all new developments of the Chemesis conveniently by mail.
Here you can subscribe to our free newsletter - LINK
Entry into the cannabis beverage and food
sector perfect For example, Chemesis recently announced its entry into the cannabis beverage sector. The company will enter the market for cannabis-added beverages. Chemesis will leverage the licenses and assets it has recently acquired to expand production, storage and a transportation network for its cannabis-infused beverages. The category of cannabis drinks includes sports drinks, teas, sodas, coffee, shots, water and other health and wellness drinks. Chemesis intends to enter the market with gums, chewy candy, chocolates, brownies, biscuits and other foods.
After the $ 5 billion investment by Constellation Brands (including Corona) in Canopy Growth (WKN A140QA) , the entire industry is in turmoil. Currently, Coca-Cola is considering a possible entry into the cannabis industry. Therefore, entering Chemesis International (WKN A2NB26) into the beverage sector has a tremendous impact , with few companies having the distribution structure and the ability to make that move!
A few days ago we introduced you to the company Chemesis International (WKN A2NB26) , after a good price increase, the stock went through a healthy consolidation around the 1 euro mark.
Massive insider buying paves the way to significantly higher prices!
Due to further insider purchases, we expect a rapid increase well above the EUR 1 mark. Although the insider Rae Venture already owns nearly 8 million of the company, a further 372,000 shares have been acquired in the market in recent days (LINK) . This shows once more how undervalued the company is currently, so we expect another steep price rise.
We also expect further significant newsflow and any further acquisitions in the coming days. Do not miss to position yourself in time.
FSD Pharma 2.0 - already more turnover and profit with ONLY 16 million outstanding shares and 50% insider participation!
Over the past few days and weeks, some cannabis stocks have literally exploded, even though many are still far from earning sales or making a profit. Companies such as FSD Pharma (WKN A2JM6M) are already valued at $ 800 million on the stock exchange and this although still no sales and profit is recorded. We have therefore made it our mission to find one of the few companies that are still undervalued and have the rapid increase in front of him.
We have found a company for you, which is valued very favorably at CAD 17 million with currently only 16 million outstanding shares (not diluted). The insiders of the company hold over 50% of all outstanding shares (LINK) . We are convinced that due to the few shares outstanding the price will rise very fast above the 1 EUR and 2 EUR mark.
Sign up for our free newsletter here - LINK
Indeed, it is expected that Chemesis International (WKN A2NB26) will post net income after tax of $ 7.492 million in the California marijuana market this year, with sales of approximately $ 21.3 million, which will be at around $ 2 million in the second year 19.1 million dollars should rise. For the fourth year, Chemesis reckoned with a net profit after tax of $ 27.2 million from California alone!
In Puerto Rico, sales are estimated to be $ 2.13 million for the first year and net income after taxes of approximately $ 309,000, compared to $ 1.87 million in year two and $ 2.86 million in year four. Dollar should rise.
Furthermore, the company plans further acquisitions in South America and Europe, do not miss out on positioning yourself in time!
Comparable companies currently have a market capitalization of at least $ 200 million. Therefore, our top pick is still very cheap and has in our opinion a catch-up potential of several 100%. It's not just us, as the company's insiders continued to buy some stocks in the market in recent days (LINK) .
Chemesis International: Ready for California Californian Cannabis Market Earning Million and Profits This Year
The California cannabis market is the largest in the world, but at the same time we believe it is still in the early stages of a massive growth cycle - and therefore the greatest opportunity for emerging cannabis companies that manage to get their foot in the door. It was only recently that we drew our readers' attention to such a company, Chemesis International (WKN A2NB26) , which is listed in Canada . Now we want to show in detail why Chemesis, in our opinion, is one of the most promising candidates in the cannabis sector.
Chemesis already operates a 20,000-square-foot, state-of-the-art, licensed manufacturing facility in Cathedral City, California, as well as a 120,000 square foot licensed cultivation and production facility in Puerto Rico for the manufacture of marijuana for medical and recreational use. The aim of the company is to become a global cannabis player!
One of the first steps in this direction was the 100% takeover of Desert Zen in early August by a manufacturer and supplier of cannabis products for Cathedral City medical and recreational use licensed by the State of California and the local community. An important step, as this acquisition allowed Chemesis to expand its resources and significantly expand its presence in the fast-growing Californian market.
Sign up for our free newsletter here - LINK
And in our view, Chemesis has made a good deal in return for the 100% stake in Desert Zen, which "spends" only 500,000 shares worth $ 1 a share, and only gradually over a period of time free from 36 months. In any case, the transaction should pay off as Desert Zen already has a large network in California that is currently serving farmers and dispensers, cooperating with other, fully regulated sales.
In addition, Desert Zen is able to track all products, monitor their safety and ensure that all laws are followed within the supply chain from seed to sale. Desert Zen's product range includes a range of different cannabis products and will also include the Chemesis premium brand California Sap (cannabis oils).
Focus on growth and execution In our view,
Chemesis International (WKN A2NB26) is in the midst of a massive growth cycle, focusing on growing premium cannabis, manufacturing cannabis extract products, distributing its products and retailing. We see this vertically integrated business model as positive as it creates new revenue opportunities, reduces costs and improves margins, which should ultimately be reflected in the bottom line.
Manufacturing is a very important facet of the business and the company has great expertise in this regard, offering its customers all sorts of extraction, recipes and products. Which represents an important competitive advantage.
In terms of distribution, Chemesis is also excellently positioned as it has long-standing relationships with distributors worldwide, according to the company. These contacts have made Chemesis a leader in Puerto Rico, and should enable it to play a leading role in California as well.
On the retail side, the cannabis industry as a whole is very profitable and, in our view, there are also great opportunities for Chemesis. Currently, Chemesis sells exclusive products in seven medical dispensaries in Puerto Rico and is actively working to be present in the Californian market as well.
And one is confident that this succeeds, as the forecasts issued in the latest presentation show. In its first year, Chemesis expects net sales in the California marijuana market of approximately $ 21.3 million after taxes of $ 7.492 million, which should increase to $ 19.1 million in the second year. For the fourth year, Chemesis reckoned with a net profit after tax of $ 27.2 million from California alone!
In Puerto Rico, sales are estimated to be $ 2.13 million for the first year and net income after taxes of approximately $ 309,000, compared to $ 1.87 million in year two and $ 2.86 million in year four. Dollar should rise.
But that should not be the end of the flagpole! As the company name implies, Chemesis relies on international growth. Only a few days ago, it announced the founding of its 100-percent subsidiary Chemesis Latin America in order to enter this interesting market. Experts predict significant growth for the South American cannabis market from $ 125 million in 2018 to $ 776 million by 2027!
An indication of the future importance of South America for the marijuana sector is that the industry leaders Canopy Growth (WKN A140QA) and Aurora Cannabis (WKN A12GS7) have recently announced steps to get the most out of their pie.
We think that Chemesis International (WKN A2NB26) israther under-valued on a sector-by-sector basis, given its long-standing and positive future prospects - the legalization of marijuana in Canada in October should also give the sector another boost.
After all, there are just 16.04 million shares outstanding at Chemesis. That means the stock market valuation is currently at just 17 million CAD! And even if you add the 46.81 million shares that will be released within 36 months, then the company brings only $ 59 million on the stock market vault with then 62.85 million shares outstanding. For competitors such as MYM Neutraceuticals (WKN A2AFCN) , however, there are CAD 113.61 million or even CAD 80.01 at Lifestyle Delivery Systems (WKN A14XHT).
In addition, Chemesis has entered into a financing agreement with Alumina Partners LLC, which has a volume of CAD 25 million. In return, Chemesis may, at its discretion, issue new shares to Alumina Partners on demand, which provides great flexibility in financing the company's expansion plans. However, Alumina receives a discount of between 15% and 25% on the shares and one warrant per share, which is 50% higher than the market price of the shares.
Chemesis International (WKN A2NB26) is an early stage of development, but given the developments and facts above, we see great opportunities for risk-taking investors looking for another high flyer in the booming cannabis sector are. We believe that the market is still (!) Underestimating this potential growth story, so we believe the current prices are suitable for building a position. We point out, however, that Chemesis is a risky speculation based, among other things, on the management's ability to implement its ambitious plans.
Register here for our free newsletter - LINK Miningstocks.expert (a trademark of First Marketing GmbH)
Daniel Muler - Chief Analyst
Botheplatz 34/1 * 69126 Heidelberg * Germany
Email: info@miningstocks.expert * Website: www.miningstocks.expert
Legal notices / Disclaimer of First Marketing GmbH
These legal notices apply to the publication and activity of First Marketing GmbH. They are to be read before reading the publications and are applicable.
1. General information
The "MiningStocks.Experts" is a trademark of First Marketing GmbH, Botheplatz 34/1, 69126 Heidelberg, www.first-marketing.de , ("First Marketing"). The First Marketing can also make publications under other brands.
First Marketing shall operate as a producer of investment strategy recommendations within the meaning of point (34) of Article 3 (1) of Regulation (EU) No 596/2014 or of investment recommendations within the meaning of point (35) of Article 3 (1) of Regulation (EU) No 596 / 2014, (previously "Financial Analyzes") of the Federal Financial Supervisory Authority ("BaFin") according to § 34c WpHG. The obligations of First Marketing are governed primarily by §§ 34b, 34c WpHG, Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/958.
2. Remuneration and reference to possible and existing conflicts of interest:
First Marketing receives compensation for the preparation, distribution and publication of its publications as well as for other services. Such compensation may be made by companies that publish First Marketing Information, third parties affiliated with such companies, or other third parties who have an interest in the companies discussed. As a result, there is a conflict of interest of First Marketing. This can first be justified by the fact that First Marketing could carry out its remarks in the interest of its client.
The clients or related persons or companies may hold shares in the company discussed at the time of this commission and may therefore be interested in a price and / or sales increase. But you may also be interested in the fact that the price of the discussed company falls if they want to buy their shares cheaper. In any case, discussing the company can significantly impact the company's share price. In particular, securities transactions also significantly influence the share price of the companies discussed. This is especially true if they are companies whose shares do not have a broad market capitalization and where there is only a narrow market. Even small order volumes can have a significant impact on prices.
First Marketing, its employees or associates as well as persons or companies involved in the preparation of the publications can at the time of publication directly or indirectly shares in the company which is reported in the context of the Internet offers. This is the case regularly. This also justifies a conflict of interests. Such shareholdings may be increased or sold, in particular by benefiting from increased trading liquidity. An increase in the price of the shares of the companies presented may lead to an increase in the capital of these persons.
Information on possible conflicts of interest pursuant to Section 85 (1) WpHG and Article 20 of Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/958:
According to § 85 of the German Securities Trading Act and the Financial Analysis Ordinance, among other things, there is an obligation to point out in a financial analysis possible conflicts of interest with regard to the analyzed company. A conflict of interest is especially suspected when the company creating the analysis
- holds a shareholding of more than 5% in the capital stock of the analyzed company,
* has been a member of a consortium which has acquired the securities of the analyzed company which manages the securities of the analyzed company on the basis of an existing contract,
- carried out investment banking services to the analyzed entity in the last 12 months on the basis of an existing contract, out of which a performance or performance promise emerged,
* entered into an agreement with the analyzed entity to prepare the financial analysis, and regularly with that affiliate Shares of the company being analyzed
* or derivatives derived therefrom, or the analyst responsible for this company has any other significant financial interests related to the company being analyzed, such as exercising mandates with the company being analyzed.
First Marketing GmbH uses the following keys to describe the conflicts of interest pursuant to Section 85 (1) WpHG and Article 20 Regulation (EU) No 596/2014 and Delegated Regulation (EU) 2016/958:
Key 1: The analyzed company has actively provided information for the preparation of this study.
Key 2: This study was sent to the analyzed company prior to distribution and changes were made thereafter. The analyzed company was not given a research report or draft that already contained an investment recommendation or a price target.
Key 5: First Marketing GmbH and / or its affiliate and / or the creator of this study has acquired shares of the analyzed company prior to its public offering free of charge or at a price below the stated target price.
Key 9: First Marketing GmbH and / or a related company has reached an agreement with the analyzed company to prepare this study. Under this agreement, First Marketing GmbH received a pre-paid fee to disseminate the analysis.
Key 11: First Marketing GmbH and / or its affiliate and / or the creator of this study holds a net sale or purchase position in the analyzed company that exceeds the threshold of 0.5% of the total issued share capital of the company - move on.
Overview of the previous investment recommendations (12 months):
Type of analysis: Date: Target price / Current:
Chemesis International First recommendation 17.09.2018 EUR 2.50 / EUR 0.65
3. Essential sources of information, reference to underlying information and forecasting character
The First Marketing publication, such as MiningStocks.Experts or other publications, is for informational purposes only of the reader.
When creating the information, First Marketing uses different sources, including company information, other publicly available information (domestic and foreign media, newspapers, financial news, etc.) and other sources. First Marketing uses only sources that are believed to be reliable and trustworthy at the time of creation. First Marketing and the persons employed by it for the preparation of the publication make every possible effort to ensure that the information used and the underlying information are as complete and factually correct as possible. Forecasts and assessments are marked and formulated accordingly. In the case of forecasts and assessments, care is also taken that these are based on factual principles and are realistic. Nevertheless, First Media assumes no responsibility for the accuracy, accuracy, completeness and adequacy of the facts presented.
4. Summary of Valuation Principles and Valuation Methods
The valuation of companies is based on a quantitative analysis of company reports and publications on the company as well as qualitative information that can be considered relevant for an assessment. Factors such as business profile, debt, loans, liquidity, earning power, business models, business performance, and similar factors.
In the case of listed companies, the assessment also takes into account the so-called technical analysis.
5. Sensitivity of the evaluation parameters - possibility of modification
The publications indicate only the assessment and opinion at the time of creation. The time of creation is stated in the publication. An obligation to update will not be accepted.
It is expressly stated that changes in the information, data and circumstances used and relied upon may occur and such changes may have a material effect on the Company's estimates and understanding.
6. Importance of recommendations
The statements and opinions of First Marketing in its publications may at best constitute a factor in the investment decision of the reader. They expressly do not constitute a recommendation to buy or sell a security. A prospect should also seek information about other sources about the company. In particular, the publications do not constitute an individual recommendation to the reader. Neither the references of the publications, nor the recommendations or opinions expressed are intended to establish a financial service of the reader, in particular an investment advisory or investment agency agreement with First Marketing or the respective author become.
The judgments are aimed at speculative private investors, but also institutional investors and professional investors. Readers should have adequate risk capital and additional assets and an investment horizon of more than five years.
In the context of the publications mean:
- Buy: Absolute upside of more than 10% within six months
- Sell: Absolute downside potential of more than 10% within six months
- Hold: Absolute potential between -10% and + 10% within six months
7. Risk instructions:
- Stock exchanges and investments in companies (stocks) are always speculative and involve the risk of total loss.
- This applies in particular to investments in companies that are not established and / or are small and have no established business operations and assets.
- Stock prices can fluctuate significantly. This applies in particular to equities that only have low liquidity (market breadth). Even small orders can have a significant impact on the share price.
- In the case of stocks in narrow markets, there may be no or very little actual trading at all and published prices are not based on actual trading but have been provided only by a stockbroker.
- A shareholder can not count on such markets to find a buyer for his shares at all and / or at reasonable prices.
- In such tight markets, there is a very high possibility of manipulation of prices and prices in such markets often lead to significant price fluctuations.
- An investment in securities with low liquidity, as well as low market capitalization is therefore highly speculative and represents a very high risk.
- There is no regulated market for unlisted shares and securities and a sale (or sale) is not possible or only on an individual basis.
8. Disclaimer:
First Marketing does not guarantee the accuracy of the opinions and opinions it gives about certain companies. It also owes no particular success if a reader should make an investment decision based on a published assessment.
Basically, a reader should only invest risk capital in stocks presented by First Marketing, ie capital he can afford a total loss on a negative track.
Any liability of First Marketing and its vicarious agents towards readers of the publications of First Marketing is excluded.
When creating the information, First Marketing uses different sources, including company information, other publicly available information, and other sources. We consider the sources we use to be reliable, but it can also lead to false information and inaccurate evaluation of information or data. The accuracy and completeness of the data and information provided to us and our assessment and opinion are not guaranteed or otherwise guaranteed by us.
Readers should therefore always evaluate the information themselves and use their own care. You should also use other sources and consultants.
All First Marketing releases are opinions and assessments at the time of publication. They are subject to change without notice, and may not be reprinted in future publications or elsewhere.
9. Responsibility according to TeleMedienGesetz (TMG)
According to § 7 Abs.1 TMG, we are only responsible for our own content on our pages according to the general laws. According to §§ 8 to 10 TMG, however, we are not obliged to monitor transmitted or stored third-party information or to investigate circumstances that indicate illegal activity. Obligations to remove or block the use of information under general law remain unaffected. However, liability in this regard is only possible from the moment of knowledge of a specific infringement. Upon notification of appropriate violations, we will remove this content immediately.
10. Liability for links
As far as our links to external websites of third parties, we point out that we have no influence on their content. Therefore, we assume no liability for these external contents. For the content of such linked pages, only the respective provider or operator is responsible. Before linking, the linked pages are reviewed for possible infringement. At this time, illegal content was not there. However, we do not carry out any constant control of such sites without concrete evidence. In the case of the existence and become aware of violations such links are removed.
11. Reference to area exclusion:
The First Marketing publications are not intended for or permitted to be distributed to persons resident or resident in the United States of America, Canada, Australia or Japan.
Auxly Cannabis Group (WKN A2DRE4), Cannabis Science (WKN A0RM6Z) . Aphria (WKN A12HM0) , The Green Organic Dutchman (WKN A2JLEE) , Tilray (WKNA2JQSC) , Aurora Cannabis (WKN A12GS7) , Liht Cannabis (WKN A2N77R) , Auxly Cannabis (WKN A2JNSX) , German Cannabis (WKN A0BVVK) , ICC International Cannabis (WKN A2N6DJ) , Global Cannabis Applications (WKN A2DQE6) , Namaste Technologies (WKN A2AEEG) , Cannabics Pharmaceuticals (WKN A116WM) , American Cannabis (WKN A12DK9) , PUF Ventures (WKN A2AMX2),